Improving bladder cancer detection with artificial intelligence
Augmented Bladder Tumor Detection Using the Bladder-Portable Artifact Detection System: A Multicentric Prospective Analytic Study Using Real Time Based Artificial Intelligence (IA).
This study is testing whether using artificial intelligence during bladder exams can help doctors find tumors more accurately and improve treatment for patients with bladder cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amiens) |
| Trial ID | NCT05415631 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the diagnosis and monitoring of bladder tumors by integrating artificial intelligence with standard bladder endoscopy. The primary goal is to reduce diagnostic errors and improve the accuracy of tumor mapping, while also standardizing the descriptive analysis of lesions. By utilizing AI, the study seeks to better characterize tumor aggressiveness and develop a new precision diagnostic tool to improve therapeutic management of bladder cancer. The approach focuses on patients with specific criteria related to tumor size and number.
Who should consider this trial
Good fit: Ideal candidates include patients with unifocal or multifocal primary or recurrent bladder cancer that meets specific size and number criteria.
Not a fit: Patients with advanced bladder cancer, evidence of distant metastases, or those who have recently undergone certain treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the accuracy of bladder cancer diagnoses, leading to better patient outcomes.
How similar studies have performed: Other studies have shown promise in using artificial intelligence for diagnostic purposes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm * multifocal primary or recurrent suspected bladder cancer less or equal than 5 lesions and with tumor size less or equal than 3 cm. Exclusion Criteria: * Evidence of more than 5 tumors or more than 3 cm * computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher) * computed tomography/magnetic resonance evidence of distant metastases (lymphatic or organic) * Exclusion criteria will include gross hematuria and bacillus Calmette-Guerin (BCG) treatment or chemotherapy within 3 months of inclusion * An exception will be made if patients had received only a single course of chemotherapy immediately following TUR * Patients objecting to the use of their data in the context of research.
Where this trial is running
Amiens
- Amiens University Hospital — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Fabien SAINT, Pr
- Email: saint.fabien@chu-amiens.fr
- Phone: 03 22 45 59 45
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.